FR940328-2-00053 FR940328-2-00032 Food and Drug Administration [Docket No. 94N&hyph;0107] Chelsea Laboratories, Inc.; Withdrawal of Approval of 26 Abbreviated New Drug Applications AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 26 abbreviated new drug applications (ANDA's) held by Chelsea Laboratories, Inc., 896 Orlando Ave., West Hempstead, NY 11552 (Chelsea). Chelsea notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn. EFFECTIVE DATE: April 27, 1994. FOR FURTHER INFORMATION CONTACT: Lola E. Batson, Center for Drug Evaluation and Research (HFD&hyph;360), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301&hyph;594&hyph;1038. SUPPLEMENTARY INFORMATION: Chelsea informed FDA that the drugs listed in the table in this document are no longer marketed and requested that FDA withdraw approval of the applications. Chelsea has also, by its request, waived its opportunity for a hearing. 1ANDA no. 1Drug 70&hyph;000 Sulfamethoxazole and Trimethoprim Tablets, U.S.P, 800 milligrams (mg)/160 mg 70&hyph;002 Sulfamethoxazole and Trimethoprim Tablets, U.S.P, 400 mg/80 mg 71&hyph;603 Clofibrate Capsules, U.S.P., 500 mg 71&hyph;635 Indomethacin Capsules, 50 mg 85&hyph;167 Procainamide Hydrochloride Capsules, U.S.P., 250 mg 85&hyph;815 Amitriptyline Hydrochloride Tablets, 50 mg 85&hyph;816 Amitriptyline Hydrochloride Tablets, 10 mg 85&hyph;817 Amitriptyline Hydrochloride Tablets, 25 mg 85&hyph;819 Amitriptyline Hydrochloride Tablets, 75 mg 85&hyph;820 Amitriptyline Hydrochloride Tablets, 100 mg 86&hyph;150 Probenecid Tablets, 500 mg 86&hyph;151 Phenylbutazone Tablets, U.S.P., 100 mg 86&hyph;161 Methylprednisolone Tablets, 4 mg 86&hyph;237 Butalbital, Aspirin, and Caffeine Tablets, U.S.P., 50 mg/325 mg/40 mg 86&hyph;705 Hydroxyzine Pamoate Capsules, U.S.P., 50 mg 86&hyph;827 Hydroxyzine Hydrochloride Tablets, U.S.P., 10 mg 86&hyph;829 Hydroxyzine Hydrochloride Tablets, U.S.P., 25 mg 86&hyph;836 Hydroxyzine Hydrochloride Tablets, U.S.P., 50 mg 86&hyph;840 Hydroxyzine Pamoate Capsules, U.S.P., 25 mg 86&hyph;865 Chlorpropamide Tablets, 100 mg 87&hyph;020 Procainamide Hydrochloride Capsules, U.S.P., 375 mg 87&hyph;021 Procainamide Hydrochloride Capsules, U.S.P., 500 mg 87&hyph;078 Spironolactone Tablets, 25 mg 87&hyph;082 Chlorthalidone Tablets, 50 mg 87&hyph;756 Phenylbutazone Capsules, U.S.P., 100 mg 87&hyph;785 Quinidine Gluconate Sustained Release Tablets, U.S.P., 324 mg Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research (21 CFR 5.82), approval of the ANDA's listed above, and all amendments and supplements thereto, is hereby withdrawn, effective April 27, 1994. Dated: March 14, 1994. Roger Williams, Acting Director, Center for Drug Evaluation and Research. [FR Doc. 94&hyph;7203 Filed 3&hyph;25&hyph;94; 8:45 am] BILLING CODE 4160&hyph;01&hyph;F
